- Natera Reports First Quarter 2024 Financial Results
- New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
- Natera to Report its First Quarter 2024 Results on May 9
- Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
- Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
- Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
- Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
- Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
- Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
- Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 108.63 |
---|---|
High | 108.75 |
Low | 106.40 |
Bid | 105.78 |
Offer | 107.13 |
Previous close | 108.50 |
Average volume | 1.59m |
---|---|
Shares outstanding | 122.24m |
Free float | 116.62m |
P/E (TTM) | -- |
Market cap | 12.63bn USD |
EPS (TTM) | -3.13 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼